Loading...
Images of Ted Fjällman
(0 from 0 )News
Chlamydia Vaccine Uses Synthetic Biology | News | SynbiCITE
www.synbicite.com
Prokarium Ltd receives funding from SynbiCITE to complete pre-clinical development of a Chlamydia vaccine, using synthetic biology, which could enter clinical...
New Vaccine For Chlamydia to Use Synthetic Biology | SCIAD
www.sciad.com
SynbiCITE funds Prokarium to complete pre-clinical development.
SynbiCITE funds new vaccine for Chlamydia | Imperial News | Imperial...
www.imperial.ac.uk
SYNBIO VACCINE TRIALS - We are delighted to announce that Prokarium, a biotechnology company developing transformational oral vaccines, will receive funding...
Prokarium receives funding to further develop new vaccine for...
www.manufacturingchemist.com
Dr Ted Fjällman, CEO of Prokarium, said the new vaccine uses synthetic biology to make the first safe and effective Chlamydia vaccine since the 1960s ...
sorted by relevance / date